ViGeneron

    OverviewSuggest Edit

    ViGeneron is a gene therapy company dedicated to developing innovative gene therapies based on AAV capsids and AAV vectors. It also offers In-house gene therapy programs focused on selected retinal disorders.
    TypePrivate
    Founded2017
    HQStarnberg, DE
    Websitevigeneron.com

    Latest Updates

    Employees (est.) (Jan 2020)4
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at ViGeneron

    Caroline Man Xu

    Caroline Man Xu

    Co-Founder and CEO
    Martin Biel

    Martin Biel

    Scientific Co-Founder
    Elvir Becirovic

    Elvir Becirovic

    Chief Technology Advisor
    Stylianos Michalakis

    Stylianos Michalakis

    Scientific Co-Founder and Chief Scientific Advisor
    Show more

    ViGeneron Office Locations

    ViGeneron has offices in Starnberg and Planegg
    Starnberg, DE (HQ)
    Riedener Weg 22
    Planegg, DE
    Semmelweisstraße 3
    Show all (2)

    ViGeneron Financials and Metrics

    Summary Metrics

    Founding Date

    2017

    ViGeneron Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    97/100

    SecurityScorecard logo

    ViGeneron Online and Social Media Presence

    Embed Graph

    ViGeneron News and Updates

    ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

    The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for …

    ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

    MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (Nasdaq: BIIB, Cambridge, Mass., USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) …

    ViGeneron Frequently Asked Questions

    • When was ViGeneron founded?

      ViGeneron was founded in 2017.

    • Who are ViGeneron key executives?

      ViGeneron's key executives are Caroline Man Xu, Martin Biel and Elvir Becirovic.

    • How many employees does ViGeneron have?

      ViGeneron has 4 employees.

    • Who are ViGeneron competitors?

      Competitors of ViGeneron include Neuexcell Therapeutics, Atsena Therapeutics and Passage Bio.

    • Where is ViGeneron headquarters?

      ViGeneron headquarters is located at Riedener Weg 22, Starnberg.

    • Where are ViGeneron offices?

      ViGeneron has offices in Starnberg and Planegg.

    • How many offices does ViGeneron have?

      ViGeneron has 2 offices.